Koninklijke Philips (ENXTAM:PHIA) Lands A U.S. Rembra CT Install, Is A 19% Discount Warranted?
Koninklijke Philips (ENXTAM:PHIA) is back in focus after Southwest Mississippi Regional Medical Center installed the first Philips Rembra CT system in a U.S. emergency department, highlighting new clinical adoption of its imaging technology.
For investors, the fresh Rembra CT win comes amid mixed recent trading in Koninklijke Philips. The company’s 1-day share price return is 1.91% and its 7-day gain is 1.25%. However, the 30-day share price return is down 5.49% and the year-to-date share price return is down 5.41%. The 3-year total shareholder return of 28.86% contrasts with a 5-year total shareholder return that declined 29.81%, which indicates recovering momentum after a tougher longer stretch.
Scan the Philips Rembra news in context by comparing Koninklijke Philips with a hand-picked group of hospital tech and imaging peers using our 134 healthcare AI stocks.
Recent share price weakness alongside the Rembra CT milestone leaves Koninklijke Philips at an interesting crossroads. Do today’s risks and mixed returns still offer enough potential reward to justify a fresh look on valuation grounds?
Most Popular Narrative: 19% Undervalued
On the most followed valuation view, Koninklijke Philips screens as undervalued, with a fair value of €27.00 against a last close of €21.87, and the Rembra CT win drops into a story that leans heavily on recurring health tech demand rather than short term trading swings.
Accelerating demand for hospital productivity and AI-enabled workflow solutions, including cloud-based Enterprise Informatics and monitoring platforms, is expected to support sustained mid-single-digit revenue growth and operating leverage as the mix of software and services increases, lifting group margins and earnings.
See why 9 investors see Koninklijke Philips as 19% undervalued.
The narrative works off a 6.43% discount rate and a fair value estimate of €27.00 per share, which is about 19% above the current €21.87 price. That gap reflects an assumption that Philips can keep converting its health technology footprint, from Diagnosis & Treatment to Connected Care and Personal Health, into steadier earnings and cash generation than the market is currently pricing.
Analysts behind this view are factoring in revenue of €17.7b today and modelling that to reach €20.0b by 2029, with earnings moving from €1.1b to €1.7b over the same window. On those numbers, the shares would trade on a P/E of 20.6x, which they see as consistent with a global medical technology group whose annual revenue growth is assumed at 4.1% and profit margin at 8.4%.
That storyline sits alongside some contrasting datapoints. Earnings for Koninklijke Philips have grown very quickly over the past year relative to its own 5 year trend, and Simply Wall St's DCF output currently flags the stock as trading at a large discount to an estimated future cash flow value of €52.27. At the same time, Philips carries a high level of debt and its forecast revenue and earnings growth are both slower than the wider Dutch market, which may help explain why the share price has not tracked the narrative fair value.
For readers weighing the Rembra CT adoption against this valuation picture, the key question is whether the health technology story around AI enabled imaging, monitoring partnerships and Exor's support for the shareholder base is strong enough to close that gap. The consensus narrative presents a case for alignment with the numbers above, while the market's current pricing still embeds a sizeable margin of caution.
Result: Fair Value of €27.00 (UNDERVALUED)
Still, the narrative around Koninklijke Philips can unravel if regulatory actions keep quality costs elevated, or if tougher hospital budgets curb demand for premium systems.
Find out about the key risks to this Koninklijke Philips narrative.
Next Steps
Neutral on the story so far or already leaning one way on Koninklijke Philips? Act while the details are fresh in your mind and weigh both sides through its 4 key rewards and 2 important warning signs
Looking for more ideas beyond Koninklijke Philips?
If Koninklijke Philips sharpened your thinking, do not stop here. Use the Simply Wall Street Screener to quickly surface fresh opportunities that fit your own risk and return preferences.
- Target higher potential upside by focusing on quality opportunities identified in our 620 high quality undiscovered gems that many investors may still be overlooking.
- Prioritise resilience by running your eye over the 226 resilient stocks with low risk scores that combine steadier fundamentals with lower overall risk profiles.
- Strengthen your income stream by scanning the 162 dividend fortresses that pair 5%+ yields with an emphasis on stability.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com